Sumita Ray

Sumita Ray is a declared insider at 2 companies; the most frequent names are Cue Biopharma, Inc. and Calithera Biosciences, Inc. We count 8 filings; the first trade dates from 27 October 2021 and the latest from 12 October 2026.

Sales make up the whole of the open-market record (4 sales, €276k). Outside the open market, there are 3 share grants and 1 option exercise. So far in 2026, the count stands at no purchases and 4 sales.

The latest filing, published on 14 October 2026, reports an open-market sale of €46k in Cue Biopharma, Inc. Filings reach the SEC (Form 4) feed a median of 4 days after the trade. Section 16 rules allow two business days to file each Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.